Ionis Pharmaceuticals (IONS) Asset Writedowns and Impairment (2015 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Asset Writedowns and Impairment of $441000.0 for Q2 2026, up 86.86% year-over-year from $236000.0 in Q2 2025, and up 1002.5% quarter-over-quarter from $40000.0 in Q1 2026.
Powered by 
Analysis
Ionis Pharmaceuticals (IONS) Asset Writedowns and Impairment (2015 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Asset Writedowns and Impairment history runs 12 years deep, the most recent figure standing at $441000.0 for Q2 2026.
- In Q2 2026, Asset Writedowns and Impairment rose 86.86% year-over-year to $441000.0; the TTM figure through Jun 2026 stood at $1.2 million (down 60.2% YoY), while the FY2025 annual figure was $986000.0, down 67.48% from the prior year.
- Asset Writedowns and Impairment for Q2 2026 stood at $441000.0, up from $40000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $4.6 million in Q4 2025, with the low at -$3.9 million in Q3 2025.
- The 5-year median for Asset Writedowns and Impairment is $293000.0 (2023), against an average of $463944.4.
- The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment soared 737.84% in 2024, then sank 735.48% in 2025.
- Ionis Pharmaceuticals' Asset Writedowns and Impairment stood at $875000.0 in 2022, then climbed by 11.2% to $973000.0 in 2023, then soared by 107.91% to $2.0 million in 2024, then surged by 128.82% to $4.6 million in 2025, then tumbled by 90.47% to $441000.0 in 2026.
- Business Quant data shows IONS's Asset Writedowns and Impairment at $441000.0 in Q2 2026, $40000.0 in Q1 2026, and $4.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Ionis Pharmaceuticals | 9.70 Bn | 7.64 Bn | 265.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 441,000.00 |
| Mar 31, 2026 | 40,000.00 |
| Dec 31, 2025 | 4.63 Mn |
| Sep 30, 2025 | -3.94 Mn |
| Jun 30, 2025 | 236,000.00 |
| Mar 31, 2025 | 61,000.00 |
| Dec 31, 2024 | 2.02 Mn |
| Sep 30, 2024 | 620,000.00 |
| Jun 30, 2024 | 256,000.00 |
| Mar 31, 2024 | 133,000.00 |
| Dec 31, 2023 | 973,000.00 |
| Sep 30, 2023 | 74,000.00 |
| Jun 30, 2023 | 330,000.00 |
| Mar 31, 2023 | 445,000.00 |
| Dec 31, 2022 | 875,000.00 |
| Sep 30, 2022 | 204,000.00 |
| Jun 30, 2022 | 841,000.00 |
| Mar 31, 2022 | 110,000.00 |
| Dec 31, 2021 | 1.56 Mn |
| Sep 30, 2021 | 323,000.00 |